Latest news for Amyris Inc (OTC:AMRSQ) Stock

Amyris Inc

<p><strong>BurgerFi International, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>, BFIIW)))) ("BurgerFi" or the "Company"), owner of the high-quality, casual dining pizza brand Anthony's Coal Fired Pizza &amp; Wings ("Anthony's") and one of the nation's leading fast-casual "better burger" dining concepts through the BurgerFi brand, announced today that the Company and Lion Point Capital, LP ("Lion Point") entered into a Settlement Agreement (the "Settlement Agreement") pursuant to which, among other things, the Company and Lion Point agreed to resolve all claims between Lion Point and the Company existing as of, or prior to, the date of the Settlement Agreement related to the previously disclosed litigation initiated by Lion Point against the Company.<br /><br />&nbsp;</p>
<p>Pursuant to the Settlement Agreement, the Company agreed to, among other things, (i) pay Lion Point $1,350,000 in installments in accordance with the schedule set forth in the Settlement Agreement, and (ii) issue to Lion Point 300,000 shares of Series A Preferred Stock (the "Preferred Shares"), in each case subject to terms and conditions set forth in the Settlement Agreement.</p>


News

Legal

BurgerFi Reaches Legal Settlement Agreement With Lion Point Capital, LP; Company Agreed To Pay Lion Point $1,350,000 In Installments In Accordance With The Schedule Set Forth In The Settlement Agreement, And Issue To Lion Point 300,000 Shares Of Series A Preferred Stock

<p>Business First Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFST#NASDAQ">BFST</a>) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.51 by 25.49 percent. This is a 8.57 percent decrease over earnings of $0.70 per share from the same period last year.  The company reported quarterly sales of $66.185 million which beat the analyst consensus estimate of $62.959 million by 5.12 percent.  This is a 1.38 percent increase over sales of $65.284 million the same period last year.</p>


Earnings

Earnings Beats

BFST

Business First Bancshares Q2 2024 Adj EPS $0.64 Beats $0.51 Estimate, Sales $66.185M Beat $62.959M Estimate

<p>Universal Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UVE#NYSE">UVE</a>) reported quarterly earnings of $1.18 per share which beat the analyst consensus estimate of $1.02 by 15.69 percent. This is a 35.63 percent increase over earnings of $0.87 per share from the same period last year.  The company reported quarterly sales of $380.214 million which beat the analyst consensus estimate of $340.090 million by 11.80 percent.  This is a 11.97 percent increase over sales of $339.570 million the same period last year.</p>


Universal Insurance Hldgs Q2 2024 Adj EPS $1.18 Beats $1.02 Estimate, Sales $380.214M Beat $340.090M Estimate

Guidance

ENSG

Ensign Group Boosts Annual Revenue Guidance From $4.13B - $4.17B To $4.20B - $4.22B (Est $4.159B)

<p>Veralto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLTO#NYSE">VLTO</a>) reported quarterly earnings of $0.85 per share which beat the analyst consensus estimate of $0.80 by 6.25 percent. This is a 6.25 percent increase over earnings of $0.80 per share from the same period last year.  The company reported quarterly sales of $1.288 billion which beat the analyst consensus estimate of $1.277 billion by 0.83 percent.</p>


VLTO

Veralto Q2 2024 Adj EPS $0.85 Beats $0.80 Estimate, Sales $1.288B Beat $1.277B Estimate

<p>Financial giants have made a conspicuous bullish move on Charter Communications. Our analysis of options history for Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) revealed 25 unusual trades.</p>
<p>Delving into the details, we found 44% of traders were bullish, while 36% showed bearish tendencies. Out of all the trades we spotted, 18 were puts, with a value of $1,900,955, and 7 were calls, valued at $621,154.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $285.0 and $350.0 for Charter Communications, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Charter Communications stands at 185.53, with a total volume reaching 9,132.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Charter Communications, situated within the strike price corridor from $285.0 to $350.0, throughout the last 30 days.</p>
<h3>Charter Communications Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721939486_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CHTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$51.3</td>
<td>$50.0</td>
<td>$50.0</td>
<td>$350.00</td>
<td>$700.0K</td>
<td>1.2K</td>
<td>316</td>
</tr>
<tr>
<td>CHTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$51.1</td>
<td>$51.0</td>
<td>$51.0</td>
<td>$350.00</td>
<td>$387.6K</td>
<td>1.2K</td>
<td>76</td>
</tr>
<tr>
<td>CHTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$16.0</td>
<td>$15.4</td>
<td>$15.5</td>
<td>$340.00</td>
<td>$387.5K</td>
<td>586</td>
<td>251</td>
</tr>
<tr>
<td>CHTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/02/24</td>
<td>$7.4</td>
<td>$6.8</td>
<td>$7.4</td>
<td>$295.00</td>
<td>$111.0K</td>
<td>2</td>
<td>208</td>
</tr>
<tr>
<td>CHTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/26/24</td>
<td>$8.1</td>
<td>$7.6</td>
<td>$7.6</td>
<td>$300.00</td>
<td>$88.1K</td>
<td>122</td>
<td>1.1K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Charter Communications</h3>
<p>Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 57 million US homes and businesses, around 40% of the country. Across this footprint, Charter serves 30 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest US cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.</p>
<p>In light of the recent options history for Charter Communications, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Charter Communications's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,385,726, with CHTR's price up by 0.82%, positioned at $315.23.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 1 days.</li>
</ul>
<h3>Expert Opinions on Charter Communications</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $278.3333333333333.</p>
<ul>
<li>Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Charter Communications, targeting a price of $330. </li>
<li>An analyst from Citigroup downgraded its action to Sell with a price target of $255. </li>
<li>An analyst from Goldman Sachs has revised its rating downward to Sell, adjusting the price target to $250. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Charter Communications with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

CHTR

Charter Communications's Options Frenzy: What You Need to Know

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Bilibili</strong>.</p>
<p>Looking at options history for Bilibili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) we detected 10 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with bullish expectations and 30% with bearish.</p>
<p>From the overall spotted trades, 4 are puts, for a total amount of $1,134,265 and 6, calls, for a total amount of $452,310.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $12.5 and $16.0 for Bilibili, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Bilibili's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bilibili's whale trades within a strike price range from $12.5 to $16.0 in the last 30 days. </p>
<h3>Bilibili Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721939481_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BILI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$1.7</td>
<td>$1.64</td>
<td>$1.69</td>
<td>$15.00</td>
<td>$642.2K</td>
<td>5.4K</td>
<td>3.8K</td>
</tr>
<tr>
<td>BILI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.42</td>
<td>$1.37</td>
<td>$1.38</td>
<td>$12.50</td>
<td>$414.0K</td>
<td>6.2K</td>
<td>3.0K</td>
</tr>
<tr>
<td>BILI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$1.48</td>
<td>$1.43</td>
<td>$1.48</td>
<td>$16.00</td>
<td>$135.9K</td>
<td>2.9K</td>
<td>2.5K</td>
</tr>
<tr>
<td>BILI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$1.44</td>
<td>$1.41</td>
<td>$1.44</td>
<td>$16.00</td>
<td>$73.4K</td>
<td>2.9K</td>
<td>1.5K</td>
</tr>
<tr>
<td>BILI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$1.45</td>
<td>$1.41</td>
<td>$1.44</td>
<td>$16.00</td>
<td>$68.5K</td>
<td>2.9K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Bilibili</h3>
<p>Bilibili is a Chinese online entertainment platform that is best known for its video-sharing site that resembles YouTube. The site was founded in 2009 and started as a long-form video platform for anime, comics, and gaming, or ACG, content that appealed to Gen Z users. Since then, it has expanded its content on the platform to include a broader range of interests that have attracted Chinese users outside of the Gen Z cohort. The firm generates revenue through five main areas: advertising, games, live streaming, value-added services, and e-commerce.</p>
<h3>Current Position of Bilibili</h3>
<ul>
<li>With a trading volume of 4,074,925, the price of BILI is up by 0.9%, reaching $14.6.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 21 days from now.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Bilibili options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


BILI

Unpacking the Latest Options Trading Trends in Bilibili

<p>The St. Joe Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOE#NYSE">JOE</a>) ("St. Joe" or "The Company") recently released its second quarter 2024 results, which showed record-breaking performance for its hospitality segment. Hospitality revenue increased by 38% to $62.3 million in the second quarter of 2024 as compared to $45.1 million in the second quarter of 2023. Similarly, gross margin for the hospitality segment increased to 39.2% for the second quarter of 2024 as compared to 26.2% for the same period in 2023. St. Joe attributes these results to several factors including new property openings in 2023, enhanced operational efficiencies at existing properties and continued increased visitation to Northwest Florida.</p>


The St. Joe Company Q2 Revenue $62.3M Vs $45.1M YoY; Q2 2024 Gross Margin For The Hospitality Segment Increased To 39.2% As Compared To 26.2% YoY

<p>Financial giants have made a conspicuous bullish move on PureCycle Technologies. Our analysis of options history for PureCycle Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) revealed 8 unusual trades.</p>
<p>Delving into the details, we found 50% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $160,330, and 6 were calls, valued at $224,495.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $2.0 to $8.0 for PureCycle Technologies over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for PureCycle Technologies's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across PureCycle Technologies's significant trades, within a strike price range of $2.0 to $8.0, over the past month.</p>
<h3>PureCycle Technologies 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721939476_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PCT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$0.7</td>
<td>$0.6</td>
<td>$0.7</td>
<td>$7.00</td>
<td>$85.3K</td>
<td>2.8K</td>
<td>1.5K</td>
</tr>
<tr>
<td>PCT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$0.7</td>
<td>$0.6</td>
<td>$0.6</td>
<td>$8.00</td>
<td>$75.1K</td>
<td>1.3K</td>
<td>2.3K</td>
</tr>
<tr>
<td>PCT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$0.7</td>
<td>$0.6</td>
<td>$0.6</td>
<td>$7.00</td>
<td>$75.0K</td>
<td>2.8K</td>
<td>1.5K</td>
</tr>
<tr>
<td>PCT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$0.7</td>
<td>$0.55</td>
<td>$0.58</td>
<td>$8.00</td>
<td>$33.6K</td>
<td>1.3K</td>
<td>571</td>
</tr>
<tr>
<td>PCT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$1.6</td>
<td>$1.35</td>
<td>$1.6</td>
<td>$8.00</td>
<td>$32.0K</td>
<td>172</td>
<td>211</td>
</tr>
</tbody>
</table>
</p>
<h3>About PureCycle Technologies</h3>
<p>PureCycle Technologies Inc holds a license to commercialize the only patented solvent-based purification recycling technology, developed by The Procter &amp; Gamble Company (P&amp;G), for restoring waste polypropylene (PP) into a virgin-like resin. The proprietary process removes color, odor, and other contaminants from recycled feedstock resulting in virgin-like polypropylene suitable for any PP market.</p>
<p>After a thorough review of the options trading surrounding PureCycle Technologies, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of PureCycle Technologies</h3>
<ul>
<li>Currently trading with a volume of 2,293,937, the PCT's price is up by 5.66%, now at $7.47. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 13 days.</li>
</ul>
<h3>What Analysts Are Saying About PureCycle Technologies</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $7.0.</p>
<ul>
<li>An analyst from Stifel has revised its rating downward to Buy, adjusting the price target to $7. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for PureCycle Technologies with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


PureCycle Technologies Unusual Options Activity

<p>AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $(0.04) by 400 percent. This is a 700 percent increase over losses of $(0.02) per share from the same period last year.  The company reported quarterly sales of $8.470 million which beat the analyst consensus estimate of $8.431 million by 0.46 percent.  This is a 8.09 percent increase over sales of $7.836 million the same period last year.</p>


AEYE

AudioEye Q2 2024 Adj EPS $0.12 Beats $(0.04) Estimate, Sales $8.470M Beat $8.431M Estimate

<p>SkyWest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYW#NASDAQ">SKYW</a>) reported quarterly earnings of $1.82 per share which beat the analyst consensus estimate of $1.74 by 4.6 percent.  The company reported quarterly sales of $867.118 million which beat the analyst consensus estimate of $826.623 million by 4.90 percent.  This is a 19.50 percent increase over sales of $725.643 million the same period last year.</p>


SKYW

SkyWest Q2 2024 GAAP EPS $1.82 Beats $1.74 Estimate, Sales $867.118M Beat $826.623M Estimate

<p>DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 10 years by 16.23% on an annualized basis producing an average annual return of 26.81%. Currently, DexCom has a market capitalization of $29.82 billion. </p>
<p><strong>Buying $100 In DXCM:</strong> If an investor had bought $100 of DXCM stock 10 years ago, it would be worth <strong>$1,081.75</strong> today based on a price of $74.99 for DXCM at the time of writing.</p>
<h3>DexCom's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721939425_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

DXCM

$100 Invested In DexCom 10 Years Ago Would Be Worth This Much Today

<p>Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 12.13% on an annualized basis producing an average annual return of 22.71%. Currently, Veeva Systems has a market capitalization of $30.16 billion. </p>
<p><strong>Buying $1000 In VEEV:</strong> If an investor had bought $1000 of VEEV stock 10 years ago, it would be worth <strong>$7,874.63</strong> today based on a price of $186.55 for VEEV at the time of writing.</p>
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721939419_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


VEEV

Here's How Much You Would Have Made Owning Veeva Systems Stock In The Last 10 Years

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LBUY"><strong>Leafbuyer Techs</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 22.22% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CNTMF"><strong>Cansortium</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 16.38% at $0.14</li>
<li><a href="https://www.benzinga.com/quote/KAYS"><strong>Kaya Holdings</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 8.57% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CLSH"><strong>CLS Holdings USA</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 6.67% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/RMHB"><strong>Rocky Mountain High</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 6.09% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/PMD"><strong>Psychemedics</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMD#NASDAQ">PMD</a>) shares closed up 4.91% at $2.17</li>
<li><a href="https://www.benzinga.com/quote/XXII"><strong>22nd Century Group</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed up 3.47% at $0.72</li>
<li><a href="https://www.benzinga.com/quote/CARA"><strong>Cara Therapeutics</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed up 3.29% at $0.37</li>
<li><a href="https://www.benzinga.com/quote/BMMJ"><strong>Body and Mind</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed up 3.29% at $0.03</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/BBRRF"><strong>Blueberries Medical</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 34.33% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/TGIFF"><strong>1933 Industries</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 15.53% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/OILFF"><strong>Nextleaf Solutions</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 11.29% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/FUAPF"><strong>Global Compliance</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed down 9.39% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/NWVCF"><strong>EnWave</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 8.04% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/GNLN"><strong>Greenlane Hldgs</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 6.52% at $0.27</li>
<li><a href="https://www.benzinga.com/quote/TCNNF"><strong>Trulieve Cannabis</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed down 4.65% at $9.93</li>
<li><a href="https://www.benzinga.com/quote/YCBD"><strong>cbdMD</strong></a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 4.40% at $0.60</li>
<li><a href="https://www.benzinga.com/quote/SNDL"><strong>SNDL</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 4.27% at $2.13</li>
<li><a href="https://www.benzinga.com/quote/CRLBF"><strong>Cresco Labs</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 4.27% at $1.57</li>
<li><a href="https://www.benzinga.com/quote/ITHUF"><strong>iAnthus Capital Hldgs</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 4.14% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/UGRO"><strong>Urban-gro</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 3.92% at $1.50</li>
<li><a href="https://www.benzinga.com/quote/CWBHF"><strong>Charlottes Web Holdings</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed down 3.50% at $0.17</li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Cannabis

Movers

BBRRF

BMMJ

CARA

CLSH

CNTMF

CRLBF

CWBHF

FUAPF

GNLN

ITHUF

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

NWVCF

OILFF

RMHB

SNDL

TCNNF

TGIFF

UGRO

XXII

YCBD

Marijuana Stock Movers For July 25, 2024

<p>Payable On August 19 To Unitholders Of Record On August 9</p>


Energy Transfer Increases Quarterly Cash Distribution To $0.32 Per Unit For Q2 2024, Up 3.2% From Last Year

WIIM

Norfolk Southern shares are trading higher after the company reported better-than-expected Q2 earnings results.

<p>Small Cap Consumer Research  analyst Eric Beder   reiterates Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) with a Buy and maintains $3 price target.</p>


Price Target

Reiteration

Analyst Ratings

VNCE

Small Cap Consumer Research Reiterates Buy on Vince Holding, Maintains $3 Price Target

<p><strong>Q3 2024 Outlook – </strong>Weyerhaeuser anticipates third quarter earnings will be approximately $10 million lower than the second quarter and Adjusted EBITDA will be approximately $30 million lower than the second quarter due to the timing and mix of real estate sales. The company now expects full year 2024 Adjusted EBITDA to be approximately $330 million, a $10 million increase from prior outlook, and continues to expect basis as a percentage of real estate sales to be 35 to 45 percent for the full year.</p>
<p><strong>Q3 2024 Outlook – </strong>Weyerhaeuser anticipates third quarter earnings before special items and Adjusted EBITDA will be lower than the second quarter, excluding the effect of changes in average sales realizations for lumber and oriented strand board. For lumber, the company expects lower sales volumes, slightly lower log costs, and higher unit manufacturing costs. For oriented strand board, the company anticipates comparable sales volumes, slightly higher fiber costs, and moderately higher unit manufacturing costs. For engineered wood products, the company expects comparable sales volumes, lower raw material costs, and moderately lower sales realizations, primarily for plywood and medium density fiberboard. For distribution, the company anticipates slightly lower results compared to the second quarter.</p>


Weyerhaeuser Sees Q3 Earnings ~$10M Lower Than Q2, Adj. EBITDA Will Be ~$30M Lower Than Q2 Due To Timing And Mix Of Real Estate Sales; Sees FY24 Adj. EBITDA ~$330M, $10M Increase From Prior Outlook, Expect Basis As A Percentage Of Real Estate Sales To Be 35%-45%

<p>Associated Banc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASB#NYSE">ASB</a>) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. This is a 7.14 percent decrease over earnings of $0.56 per share from the same period last year.  The company reported quarterly sales of $321.752 million which missed the analyst consensus estimate of $330.872 million by 2.76 percent.  This is a 0.53 percent decrease over sales of $323.460 million the same period last year.</p>


Earnings Misses

Associated Banc Q2 2024 GAAP EPS $0.52, Inline, Sales $321.752M Miss $330.872M Estimate

Dexcom Sees FY24 Revenue $4.00B-$4.05B vs $4.33B Est.

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><span>Investing in <a href="https://investorplace.com/industries/healthcare/biotech/">biotec</a>h stocks is not for the meek. Losses can be very large and occur very quickly. In fact, I&rsquo;ve uncovered seven of the top biotech stocks to sell as we get into the final months of the year. &nbsp;Some of the top ones include:</span></p>
<h2><strong>Biotech Stocks to Sell: HOOKIPA Pharma (HOOK)</strong></h2>
<div><img src="https://investorplace.com/wp-content/uploads/2023/03/two-men-stocks-down-red-arrow-1600-300x169.jpg" alt="Figurines of two little men in suits looking at downward stock arrow going through the floor. overvalued stocks" width="300" height="169"><div>Source: shutterstock.com/Black Salmon</div></div>
<p><b>HOOKIPA Pharma</b><span> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/hook-stock-quote/"><strong>HOOK</strong></a></span>) is developing a novel platform for therapies aimed at commercializing immunotherapeutics for cancer. After all, such therapies can&nbsp;</span><span>stimulate an immune response, and help find and attack cancer cells. If HOOKIPA Pharma commercializes such therapeutics, it stands to do very well. However, to achieve its goal, it will burn through a lot of cash in the process.&nbsp;</span></p>
<p><span>That isn&rsquo;t to say that the company is facing a liquidity crisis at the moment. In fact, there doesn&rsquo;t appear to be an emergent liquidity crisis at all. Instead,&nbsp;HOOKIPA Pharma has enough money to continue to stay afloat for at least a year and a half. However, <a href="https://www.hookipapharma.com/our-programs/our-pipeline/" target="_blank">if you look at its pipeline</a>&nbsp;it&rsquo;s pretty clear that the company doesn&rsquo;t have any obvious commercialization prospects within that timeframe. Thus, it could very possibly continue to bleed cash and simply never commercialize.&nbsp;</span></p>
<h2><strong>Amyris (AMRSQ)</strong></h2>
<div><img src="https://investorplace.com/wp-content/uploads/2023/03/stocks-red-down-bearish-hands-1600-300x169.jpg" alt="Grayish photo of investor's hands hovering over laptop with red stock graph showing downward arrow overlayed on top of the image" width="300" height="169"><div>Source: shutterstock.com/Leonid Sorokin</div></div>
<p><b>Amyris</b><span> (OTCMKTS:<span><a href="https://investorplace.com/stock-quotes/amrsq-stock-quote/"><strong>AMRSQ</strong></a></span>) undertook voluntary <a href="https://investors.amyris.com/2023-08-09-AMYRIS-ANNOUNCES-OPERATIONAL-AND-FINANCIAL-RESTRUCTURING-TO-ADVANCE-STRATEGIC-TRANSFORMATION">Chapter 11 restructuring</a> in early August, which tanked the stock. From here, It&rsquo;s difficult to see how the restructuring could plausibly lead to a better business moving forward. Thus, investors should stay away even as low prices make it increasingly tempting.&nbsp;</span></p>
<p><span>The company is selling off its brands and intends to refocus on all of the business process competencies it has built experience in. That means the company will sell its sustainable synthetic ingredients businesses and start over in an effort to build the same business again. It begs the obvious question of why investors should believe in it this time. Fool me once, shame on you, fool me twice, shame on me.&nbsp;</span></p>
<p><span>Amyris&rsquo; business idea certainly had and continues to have merit. The company produces synthetic versions of natural ingredients like squalene that result in animal deaths. Most investors would be interested in contributing to businesses that achieve that goal assuming the products are equivalent. It&rsquo;s a noble goal but it clearly hasn&rsquo;t resulted in a fiscally sustainable business model.&nbsp;</span></p>
<h2><strong>Biotech Stocks to Sell: Novavax (NVAX)</strong></h2>
<div><img src="https://investorplace.com/wp-content/uploads/2019/07/sell-kid-thumbs-down-300x169.jpg" alt="little girl holding a stock chart with athumbs down. tech stocks" width="300" height="169"><div>Source: Shutterstock</div></div>
<p><b>Novavax</b><span> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nvax-stock-quote/"><strong>NVAX</strong></a></span>) is another one of the top biotech stocks to sell. The company was the fourth to receive US FDA approval to market its Covid-19 vaccine. And many investors saw the victory as being too little, too late. The company&rsquo;s losses served to bolster that notion. However, Novavax staged something of a turnaround in Q2, posting profits.&nbsp;</span></p>
<p><span>As positive as that seems, Novavax continues to head downward overall. There is perhaps no more convincing piece of evidence for that assertion than a <a href="https://ir.novavax.com/press-releases/2023-08-08-Novavax-Reports-Second-Quarter-2023-Financial-Results-and-Operational-Highlights" target="_blank">continued sales decline</a>. Novavax is expected to experience declining sales throughout 2024. In other words, the net income the firm showed in Q2 is arguably a false flag.&nbsp;</span></p>
<p><span>The company is expected by most analysts to see shrinking revenues in 2024. <a href="https://finance.yahoo.com/quote/NVAX/analysis?p=NVAX" target="_blank">Novavax is expected to produce $1.36 billion in sales in 2023</a>. That number is expected to fall to $1.29 billion next year. It&rsquo;s also highly variable with a range between $756 million to $2.4 billion. It could explode upward or implode dramatically. Given the high short interest in the shares currently, I&rsquo;d bet on the latter occurring.&nbsp;</span></p>
<h2><strong>Seelos Therapeutics (SEEL)</strong></h2>
<div><img src="https://investorplace.com/wp-content/uploads/2019/07/sell-man-distress-arrow-down-300x169.jpg" alt="a frustrated man with a white board behind him that features a black downward arrow" width="300" height="169"><div>Source: Shutterstock</div></div>
<p><b>Seelos Therapeutics</b><span> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/seel-stock-quote/"><strong>SEEL</strong></a></span>) should also be avoided. At the moment, Its research touches on interesting pressing unmet needs like Amyotrophic Lateral Sclerosis (ALS) and the use of ketamine for mental health issues. Those issues are gaining traction which in turn attracts investors. However, Seelos Therapeutics as a business has done very little to substantiate it as an investment.&nbsp;</span></p>
<p><span>Sure, it&rsquo;s an interesting idea but has very unattractive results. Nothing better substantiates than the fact that as of June 30, the company had <a href="https://www.sec.gov/Archives/edgar/data/1017491/000141057823001773/seel-20230630x10q.htm">$5.8 million in cash</a> and an accumulated deficit of $257.7 million. It is a going concern and the same 10-Q notes that the company may never reach profitability and expects to continue to incur significant losses.&nbsp;</span></p>
<p><span>Losses increased in the most recent 6-month period. The company issues stock and warrants to fund increasingly larger losses. Thus, holders of that stock and those warrants are continually subsidizing a company headed in the wrong direction.&nbsp;</span></p>
<h2><strong>Invivyd (IVVD)</strong></h2>
<div><img src="https://investorplace.com/wp-content/uploads/2019/07/sell-red-dice-300x169.jpg" alt="earnings" width="300" height="169"><div>Source: Shutterstock</div></div>
<p><b>Invivyd</b><span> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ivvd-stock-quote/"><strong>IVVD</strong></a></span>) is a small biotech firm developing coronavirus therapeutics. And it should be avoided. The company has unsuccessfully attempted to leverage the pandemic to propel its business.&nbsp;</span></p>
<p><span>The firm rebranded back in 2020 from its former name, <a href="https://www.fiercepharma.com/marketing/adagio-finds-new-composition-its-marches-fresh-beat-invivyd" target="_blank">Adagio Therapeutics</a>. At that time, optimism surrounding its <a href="https://www.marketwatch.com/press-release/invivyd-announces-additional-positive-initial-data-from-ongoing-phase-1-clinical-trial-of-vyd222-a-monoclonal-antibody-candidate-in-development-for-the-prevention-of-symptomatic-covid-19-in-immunocompromised-people-4356d865" target="_blank">lead candidate drug adintrevimab</a> was waning. Its CEO left, and the company hasn&rsquo;t done much in the interim. It is closer to commercializing adintrevimab for Covid-19 but it&rsquo;s simply too late. The potential revenues from that application aren&rsquo;t what they used to be. Firms including Invivyd that attempted to make it big off the pandemic continue to fall off.&nbsp;</span></p>
<p><span>The company has a cash runway through Q4 2024 but that should provide little consolation for investors. Invivyd is chasing emergency use authorization (EUA) as 2024 nears. The pandemic is officially over and very few people are concerned about the health threat now. The economic effects matter but that isn&rsquo;t what Invivyd is addressing.&nbsp;</span></p>
<h2><strong>Zomedica (ZOM)</strong></h2>
<div><img src="https://investorplace.com/wp-content/uploads/2019/07/sell-button-300x169.jpg" alt="a keyboard with a greet enter key marked sell, representing overvalued stocks to sell" width="300" height="169"><div>Source: Shutterstock</div></div>
<p><span>The last time I wrote about </span><b>Zomedica</b><span> (NYSEAMERICAN:<span><a href="https://investorplace.com/stock-quotes/zom-stock-quote/"><strong>ZOM</strong></a></span>) was prior to the <a href="https://finance.yahoo.com/news/zomedica-announces-first-commercial-sale-100000980.html#:~:text=ANN%20ARBOR%2C%20Mich.%2C%20March,%C2%AE%20and%20officially%20entered%20commercialization." target="_blank">commercialization of its TRUFORMA diagnostic platform</a> in veterinary medicine. </span><span>The platform provides quick on-site testing for thyroid and adrenal issues for use in cats and dogs. Its benefit is that such testing is generally required to be sent to off-site labs for analysis. This can result in errors being introduced and time lost. Truforma solves those issues.&nbsp;</span><span>However, it hasn&rsquo;t managed to achieve much commercial success as adoption simply hasn&rsquo;t materialized. Zomedica&rsquo;s opportunity was in commercializing TRUFORMA and that doesn&rsquo;t look likely to happen.&nbsp;</span></p>
<h2><strong>Moderna (MRNA)</strong></h2>
<div><img src="https://investorplace.com/wp-content/uploads/2019/07/sell-chalk-board-300x169.jpg" alt="sell written on a chalkboard representing overvalued stocks to sell" width="300" height="169"><div>Source: Shutterstock</div></div>
<p><b>Moderna</b><span> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/mrna-stock-quote/"><strong>MRNA</strong></a></span>) was one of the pandemic winners. It was one of the big COVID-19 firms to initially commercialize a vaccine. That propelled it from a relative unknown to a stock worth nearly $500. Now, it&rsquo;s sliding back the other way and should be avoided.&nbsp;</span></p>
<p><span>The company produced $36 billion in revenues over the last two years. It&rsquo;s on track to post about <a href="https://finance.yahoo.com/quote/MRNA/analysis?p=MRNA">$7 billion</a> this year and $6 billion next year. Although it has a deep pipeline of drugs based on mRNA therapy, it&rsquo;s basically only COVID-19 revenues that prop it up. I don&rsquo;t need to beat a dead horse in regard to that shrinking opportunity or explain why that is.&nbsp;</span><span>The company is now losing a lot of money. It reported <a href="https://investors.modernatx.com/news/news-details/2023/Moderna-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Updates/default.aspx">a $1.38 billion loss</a> in Q2. Pandemic profits are dying and so is Moderna.&nbsp;</span></p>
<p><i><span>On the date of publication, Alex Sirois did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</span></i><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><i><span> Publishing Guidelines</span></i></a><i><span>.</span></i></p>
<div>
<p>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</p>
</div>
<h3>More From InvestorPlace</h3>
<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT758389">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT758391">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT758395">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
</ul><div>
<div>
<div></div>
<div></div>
</div>
</div>

<p>The post <a href="https://investorplace.com/2023/09/7-biotech-stocks-to-sell-in-september-before-they-crash-burn/">7 Biotech Stocks to Sell in September Before They Crash &amp; Burn</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Biotech Stocks to Sell in September Before They Crash & Burn

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Synthetic biology refers to using engineered organisms to produce products for multiple industries. Specifically, the pharmaceutical, biotechnology, and agriculture sectors are set to benefit most from synthetic biology.</p>



<p>These are high-risk stocks overall. Firms in this industry face significant hurdles to reach commercialization. They also aim to solve high-impact problems. For that reason and others, they have serious potential to produce dramatic returns. Synthetic biology stocks will continue to be highly attractive in 2023 and beyond for investors with higher risk tolerances. Let&rsquo;s look at a handful of those companies that currently show strong potential.</p>



<h2>Codexis (CDXS)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>


<p><strong>Codexis</strong>&nbsp;(NASDAQ:<a target="_blank" href="https://investorplace.com/stock-quotes/cdxs-stock-quote/"><strong>CDXS</strong></a>) is a producer of enzymes and biopharmaceuticals. The company&rsquo;s main product is its enzyme engineering platform called CodeEvolver.&nbsp;</p>



<p>CodeEvolver allows firms to manufacture synthetic enzymes more efficiently than their natural counterparts. Another major benefit of synthetic enzymes is that they can be engineered to be more stable than in their natural form. CodeEvolver is attractive for that reason and allows enzymes that have a significantly extended shelf life relative to natural enzymes to be made.</p>



<p>The company is also developing another platform called ECO Synthesis, which manufactures RNAi therapeutics. The company expects that platform to be ready for Production purposes by the end of the year. RNAi stands for RNA interference and interrupts the expression of target genes.</p>



<p>Company-wide revenues have decreased this year but the company maintains a strong&nbsp;<a target="_blank" href="https://www.wsj.com/market-data/quotes/CDXS/research-ratings">outlook</a>&nbsp;on Wall Street. Further, Codexis has given guidance that it anticipates positive cash flow by the end of 2026. Based on ratings alone, it&rsquo;s reasonable to anticipate that an investment in Codexis could create 200% returns.</p>



<h2>Ginkgo Bioworks (DNA)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/dna_ginkobioworks1600-300x169.png" alt="Person holding mobile phone with logo of American biotechnology company Ginkgo Bioworks Inc. on screen in front of web page. Focus on phone display. Unmodified photo. DNA stock"><div>Source: T. Schneider / Shutterstock.com</div></div>


<p><strong>Ginkgo Bioworks</strong>&nbsp;(NYSE:<a target="_blank" href="https://investorplace.com/stock-quotes/dna-stock-quote/"><strong>DNA</strong></a>) Is among the more prominent stocks in the synthetic biology space. The company is located in Boston, Massachusetts, which is a leading hub in the biotechnology industry.</p>



<p>Ginkgo Bioworks is developing a platform that promises to, in the words of the company, enable customers to program cells as easily as we program computers. Like Codexis, Ginkgo Bioworks also enjoys a strong&nbsp;<a target="_blank" href="https://www.wsj.com/market-data/quotes/DNA/research-ratings">potential upside</a>&nbsp;based on Wall Street estimates.</p>



<p>Fundamentally, Ginkgo Bioworks is currently working through some issues.&nbsp;<a target="_blank" href="https://investors.ginkgobioworks.com/news/news-details/2023/Ginkgo-Bioworks-Reports-Third-Quarter-2023-Financial-Results/default.aspx">Revenues</a>&nbsp;in the third quarter fell from $66 million to $55 million. That said, there continues to be plenty of room for optimism regarding the company&rsquo;s stock.&nbsp;</p>



<p>The company added 21 new programs to its Foundry Platform, representing 40% growth. Further, it partnered with&nbsp;<strong>Alphabet</strong>&nbsp;(NASDAQ:<a target="_blank" href="https://investorplace.com/stock-quotes/goog-stock-quote/"><strong>GOOG</strong></a>, NASDAQ:<a target="_blank" href="https://investorplace.com/stock-quotes/googl-stock-quote/"><strong>GOOGL</strong></a>) which leverages the firm&rsquo;s cloud capabilities.</p>



<p>Most importantly, Ginkgo Bioworks entered into an agreement with&nbsp;<strong>Pfizer</strong>&nbsp;(NYSE:<a target="_blank" href="https://investorplace.com/stock-quotes/pfe-stock-quote/"><strong>PFE</strong></a>) during the quarter. That agreement Includes potential developmental and commercial milestone payments worth as much as $331 million.&nbsp;</p>



<h2>Amyris (AMRSQ)</h2>


<div>
<a href="https://investorplace.com/wp-content/uploads/2023/01/shutterstock_2007284921-scaled-e1673028735742.jpg"><img width="300" height="214" src="https://investorplace.com/wp-content/uploads/2023/01/shutterstock_2007284921-scaled-e1673028735742-300x214.jpg" alt="A plant grows out of a crack in the pavement."></a></div>


<p><strong>Amyris</strong>&nbsp;(OTCMKTS:<a target="_blank" href="https://investorplace.com/stock-quotes/amrsq-stock-quote/"><strong>AMRSQ</strong></a>) Is the riskiest stock on this list of already risky stocks. The company leverages plant-based sugars to produce Synthetic chemicals. The company then sells those synthetic chemicals into end markets including cosmetics, fragrances, flavors and nutraceuticals.</p>



<p>The company voluntarily&nbsp;<a target="_blank" href="https://investors.amyris.com/2023-08-09-AMYRIS-ANNOUNCES-OPERATIONAL-AND-FINANCIAL-RESTRUCTURING-TO-ADVANCE-STRATEGIC-TRANSFORMATION">entered</a>&nbsp;Chapter 11 bankruptcy, which provided for restructuring. The decision to do so caused its share prices to plummet dramatically. When the announcement was made in early August share prices fell from 59 cents to one penny. Investors can pick up shares at that price currently.</p>



<p>Thus, there&rsquo;s a very reasonable argument to be made that Amyris continues to be a worthwhile investment. One reason to believe that is based on the lone Wall Street&nbsp;<a target="_blank" href="https://www.wsj.com/market-data/quotes/AMRSQ/company-people">rating</a>&nbsp;on its stock. That rating&nbsp;<a target="_blank" href="https://www.wsj.com/market-data/quotes/AMRSQ/company-people">values</a>&nbsp;Amyris stock at $1.50. Thus, it&rsquo;s mathematically feasible that an investment of $6,667 could turn into $1 million.</p>



<p>The company intends to restructure in order to focus on biofermentation as the main driver of its business. At one penny it remains one of the more interesting synthetic biology stocks available to investors.&nbsp;</p>



<p><em>On the date of publication, Alex Sirois did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em><a target="_blank" href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em>&nbsp;Publishing Guidelines</em></a><em>.</em></p>
<div><p>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT766529">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2023/11/3-synthetic-biology-stocks-likely-to-mint-new-millionaires/">3 Synthetic Biology Stocks Likely to Mint New Millionaires</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Synthetic Biology Stocks Likely to Mint New Millionaires

Dr. Reddy's acquires MenoLabs business from Amyris

Amyris (AMRSQ) has released an update. The Company is set to deregister its securities, a move that follows the effectiveness of a restructuring pl...

Amyris Announces Securities Deregistration Post-Restructuring

Amyris (AMRSQ) has released an update to notify the public and investors about termination and asset disposition expenses. In a significant move, a...

Amyris Announces Layoffs, Forecasts $1M Q1 Charge

Amyris (AMRSQ) has released an update to notify the public and investors about its debt resolution strategies. Amyris, Inc., a company that filed f...

Amyris Receives Court Approval for Restructuring Plan

An update from Amyris (AMRSQ) is now available. The Company recently submitted its monthly operating report for a one-month period to the Bankruptc...

Amyris Advises Caution to Investors Amid Bankruptcy Proceedings

Amyris (AMRSQ) has provided an update. Amyris, Inc. and its subsidiaries, in the midst of Chapter 11 bankruptcy proceedings, urge caution to invest...

Amyris Warns Investors Amid Bankruptcy Proceedings

Amyris (AMRSQ) has provided an update. Amyris, Inc. and its subsidiaries, under Chapter 11 bankruptcy since August 9, 2023, submitted their Februar...

Amyris Cautions Investors in February Financial Report

Amyris (AMRSQ) just unveiled an update. AB Technologies LLC and its subsidiaries have successfully restructured their debt through an amended loan ...

Amyris Restructures Debt, Issues Stock, and Streamlines Operations

AMRSQ

CDXS

GOOG

GOOGL

HOOK

IVVD

MRNA

NVAX

SEEL

<p>Ameris Bank ("Ameris" or the "Bank"), the wholly owned subsidiary of Ameris Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABCB#NASDAQ">ABCB</a>), today announced that it has entered into a settlement with the U.S. Department of Justice that resolves&nbsp;alleged&nbsp;violations of fair lending laws in the Jacksonville, Florida metropolitan area from 2016 to 2021. As noted in the Consent Order resolving the case, Ameris firmly denies violating, and maintains that it has consistently complied with, applicable fair lending laws.</p><p>"We strongly disagree with any suggestion that we have engaged in discriminatory conduct and are confident in our efforts to provide equal access to affordable mortgage products in the Jacksonville community and all the markets we serve," said Palmer Proctor, CEO of Ameris. "We cooperated fully with the Department's inquiry and have entered into this settlement to avoid the distraction of litigation and because we share the Department's goal of expanding access to homeownership in underserved areas. The terms of this settlement are consistent with the Bank's existing programs and initiatives. We condemn discrimination in any form and remain committed to helping people in underserved communities gain equal opportunity to achieve homeownership, as well as access to banking services."</p><p>Under the terms of the settlement, Ameris will provide <strong>$7.5 million</strong> in mortgage loan subsidies over a five-year period in Majority Black and Hispanic Census Tracts ("MBHCTs") in Jacksonville. The Bank will also commit, for the same five-year period in the Jacksonville MBHCT communities, <strong>$900,000</strong> for focused advertising and outreach and <strong>$600,000</strong> for community development partnerships providing services related to credit, financial education, homeownership, and foreclosure prevention. These efforts will supplement the Bank's current investments in mortgage loan subsidy programs and ongoing marketing and community outreach across the markets it serves.</p><p>The settlement does not include any civil monetary penalties against Ameris.&nbsp;</p><p>"With a 52-year history of service, Ameris is rooted in its purpose of bringing financial peace of mind to people and communities," Proctor added. "Over the years, this purpose has led us to introduce various mortgage loan and downpayment assistance programs, develop affordable loan opportunities, and deliver financial education to schools and community groups. We look forward to continuing these proactive efforts and helping more consumers achieve their financial goals."</p>

ABCB

Ameris Bank Announces Settlement With Department Of Justice; Ameris Will Provide $7.5M In Mortgage Loan Subsidies Over A 5-Year Period In Majority Black And Hispanic Census Tracts In Jacksonville

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Amyris Inc

News

Latest news for Amyris Inc (OTC:AMRSQ) Stock

Thursday, October 19, 2023